Physician profile
Shannon E Brophy
NPI 1891731642
$5,028.04
in general payments reported to CMS, 2019-2025
26 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $716 · 2023: $1,141 · 2024: $1,155 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,683 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.28 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,291.57 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $1,166.38 | 2021-2025 | Xcopri |
| Neurelis, INC. | $765.82 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $342.53 | 2022-2025 | |
| Aucta Pharmaceuticals, INC. | $281.16 | 2024-2025 | Motpoly Xr |
| Otter Pharmaceuticals, LLC | $183.91 | 2025 | Sympazan |
| Sumitomo Pharma America, INC. | $159.29 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $128.61 | 2021-2022 | |
| Livanova USA, INC. | $94.89 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $68.94 | 2021 | |
| Eisai INC. | $61.66 | 2022 | |
| Aquestive Therapeutics, INC. | $57.25 | 2022 | |
| Azurity Pharmaceuticals, INC. | $54.38 | 2023-2025 | Zonisade, Eprontia |
| Aprecia Pharmaceuticals, LLC | $51.89 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $51.00 | 2024-2025 | Subvenite |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nobelpharma America, LLC | $41.26 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $33.80 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $32.27 | 2023-2024 | Fycompa |
| Celgene Corporation | $30.00 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $26.15 | 2024 | Brineura |
| Biocodex, INC. | $22.30 | 2025 | |
| Boston Scientific Corporation | $20.87 | 2024 | |
| Pfizer INC. | $18.05 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Ptc Therapeutics, INC. | $14.95 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Brophy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.